Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Grants Orphan Drug Designation to Efineptakin Alfa for Pancreatic Cancer

February 2nd 2024

Efineptakin alfa received an orphan drug designation from the FDA for use as a potential therapeutic option in patients with pancreatic cancer.

Dr Bryant on the Background For Investigating Germline DNA Repair Mutations in PDAC

February 2nd 2024

John Michael Bryant, MD, discusses the effects of germline DNA repair mutations on radiosensitivity in patients with pancreatic ductal adenocarcinoma.

FDA Grants Fast Track Designation to BST02 for Liver Cancer

February 1st 2024

The FDA has granted a fast track designation to the T-cell therapy BST02 for the treatment of patients with all forms of liver cancer.

Updated CheckMate 649 Data Reinforce Nivolumab Plus Chemo as Frontline SOC in Advanced Gastric Cancers

February 1st 2024

Kohei Shitara, MD, discusses 4-year survival data of chemotherapy plus nivolumab in advanced gastric/GEJ cancer or esophageal adenocarcinoma.

Symptoms Associated With Eye-Related Toxicities Amid FGFRi Therapy

January 31st 2024

Ocular toxicities from dry eye to development of cataracts are potential risks with FGFRi treatment; providers share management strategies.

Patient Perspective Regarding FGFRi Adverse Event Profiles

January 31st 2024

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events.

Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study

January 30th 2024

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Dr Sahin on the Potential Use of Northstar Response in GI Cancer

January 29th 2024

Ilyas Sahin, MD, discusses an assessment of the Northstar Response in patients with advanced gastrointestinal cancer undergoing active treatment.

Common Adverse Events Associated With FGFRi Therapy

January 24th 2024

A review of how frequently adverse events from hyperphosphatemia to nail toxicities to stomatitis and more.

Key Highlights For Patient Education Surrounding FGFR Inhibitors

January 24th 2024

Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors.

Dr Melstrom on Challenges Implementing Widespread Molecular Testing in GI Cancer

January 22nd 2024

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

ctDNA Is Predictive of DFS, Offers Prognostic Tool in CRC

January 20th 2024

Minimal residual disease detection by ctDNA was predictive and prognostic of disease recurrence and response to adjuvant chemotherapy in patients with CRC.

Real-World Data Identify Factors Associated With Long-Term Response to Regorafenib in mCRC

January 20th 2024

Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.

Larotrectinib Displays Efficacy, Tolerability in TRK Fusion+ Gastrointestinal Cancers

January 20th 2024

Larotrectinib led to long-lasting responses, encouraging survival, and a favorable safety profile in TRK fusion-positive gastrointestinal cancers.

177Lu-Dotatate Prolongs PFS Vs High-Dose Octreotide in GEP-NETs

January 20th 2024

Lutetium Lu 177 dotatate plus octreotide significantly improved PFS vs high-dose octreotide in patients with gastroenteropancreatic neuroendocrine tumors.

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

January 20th 2024

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization.

FOLFOXIRI Plus Bevacizumab Use Rises Over Time in mCRC

January 20th 2024

The use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer from 2013 to 2022, especially in patients 50 years of age or younger.

Dr Shitara on the 4-Year Outcomes of the CheckMate 649 Trial in GEJ Adenocarcinoma

January 20th 2024

Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.

Fostrox/Lenvatinib Combination Displays Efficacy, Tolerability in Pretreated HCC

January 19th 2024

Fostroxacitabine bralpamide plus lenvatinib displayed preliminary efficacy with a tolerable safety profile in patients with hepatocellular carcinoma.

Frontline Pembrolizumab Plus Lenvatinib Maintains Efficacy, Shows Promising DOR in Advanced HCC

January 19th 2024

Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.